NCT02740634Recruiting
Molecular and Structural Imaging in Alzheimer's Disease: A Longitudinal Study
Source: ClinicalTrials.gov · Last updated 17 Jul 2026
Brief summary (registry, in English)
This is a neuroimaging study designed to learn more about amyloid and tau burden in the brain of patients with typical and atypical Alzheimer's Disease and how burden may change over a one year period.
- Status (registry)
- Recruiting
- Study type
- Interventional
- Enrollment
- 60 (estimated)
- First submitted
- 7 Apr 2016
- Start date
- May 2016
- Primary completion date
- Mar 2027
- Lead sponsor
- Mayo Clinic
- Diseases
- Alzheimer disease
- NCT number
- NCT02740634
What you commit to
- Study type: Interventional
- Planned participants: 60
- From May 2016 to the primary completion date, Mar 2027
- 1 site in 1 country
- Visits and tests: ask the trial team, the registry does not list them
Built from the registry fields of ClinicalTrials.gov. It describes the study, not your situation.
Who cannot take part
Copied verbatim from ClinicalTrials.gov and grouped by topic. Only the trial team decides who can take part.
Other illness
- If you have had a stroke or tumor that could explain your symptoms
- Subjects that present with early episodic memory impairment or meet clinical criteria for mild cognitive impairment will not be recruited into the study
- Subjects that meet specific criteria for another neurodegenerative disorder, including behavioral variant frontotemporal dementia, semantic dementia, primary progressive apraxia of speech, probable corticobasal syndrome, or progressive supranuclear palsy, will be excluded
- Subjects will also be excluded if MRI is contraindicated (metal in head, cardiac pace maker, e.t.c.), if there is severe claustrophobia, if there are conditions that may confound brain imaging studies (e.g. structural abnormalities, including subdural hematoma or intracranial neoplasm), or if they are medically unstable or are on medications that might affect brain structure or metabolism,(e.g. chemotherapy)
Lab values
- Subjects will be excluded from the study if they are unable to undergo the tau-PET scan due to a prolonged QT interval on ECG, or if they have any of the following genetic conditions which can increase the chance of cancer: Cowden disease, Lynch syndrome, hypogammaglobulinemia, Wiskott-Aldrich syndrome, and Down's syndrome
Other
- Subjects will be excluded if they have poor vision (20/400)
- Women that are pregnant or post-partum and breast-feeding will be excluded
Who the study is looking for
- Over the age of 21
- Must have an informant who will be able to provide independent evaluation of functioning
- English is primary language
- All subjects must have insidious onset, report progression of their symptoms, and meet current clinical diagnostic criteria for typical amnestic AD or an atypical AD syndrome such as Logopenic Aphasia (LPA) or Posterior Cortical Atrophy (PCA).
- All subjects with Logopenic Aphasia (LPA) must present with early and dominant impairments in language
- All subjects with typical amnestic AD must have relative preservation of episodic memory compared to impairment in the non-episodic memory domain
Age in the registry: 21 years to 80 years · Sex: All · Does not accept healthy volunteers
Sites (1)
Sites in registry order. Pick your city on the disease page to sort them by distance.
| Site | City | Country | Site status |
|---|---|---|---|
| Mayo Clinic Coordinator of this site? Confirm its status | Rochester | United States | Recruiting |
This page is information, not medical advice. Discuss any trial with your doctor.